Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn

Susceptibility of methionine residues to oxidation is a significant issue of protein therapeutics. Methionine oxidation may limit the product's clinical efficacy or stability. We have studied kinetics of methionine oxidation in the Fc portion of the human IgG2 and its impact on the interaction with FcRn and Protein A. Our results confirm previously published observations for IgG1 that two analogous solvent‐exposed methionine residues in IgG2, Met 252 and Met 428, oxidize more readily than the other methionine residue, Met 358, which is buried inside the Fc. Met 397, which is not present in IgG1 but in IgG2, oxidizes at similar rate as Met 358. Oxidation of two labile methionines, Met 252 and Met 428, weakens the binding of the intact antibody with Protein A and FcRn, two natural protein binding partners. Both of these binding partners share the same binding site on the Fc. Additionally, our results shows that Protein A may serve as a convenient and inexpensive surrogate for FcRn binding measurements.

[1]  Da Ren,et al.  Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. , 2008, Biochemistry.

[2]  E. Komives,et al.  NMR structures reveal how oxidation inactivates thrombomodulin. , 2003, Biochemistry.

[3]  Terrence G. Oas,et al.  Methionine oxidation of monomeric λ repressor: The denatured state ensemble under nondenaturing conditions , 2006 .

[4]  Pamela J. Bjorkman,et al.  Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.

[5]  E. Shacter.  QUANTIFICATION AND SIGNIFICANCE OF PROTEIN OXIDATION IN BIOLOGICAL SAMPLES* , 2000, Drug metabolism reviews.

[6]  G Shimamoto,et al.  Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. , 1999, Archives of biochemistry and biophysics.

[7]  S. Hober,et al.  Protein A chromatography for antibody purification. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  Baowei Chen,et al.  Structural uncoupling between opposing domains of oxidized calmodulin underlies the enhanced binding affinity and inhibition of the plasma membrane Ca-ATPase. , 2005, Biochemistry.

[9]  M. Uhlén,et al.  Staphylococcal protein A consists of five IgG-binding domains. , 1986, European journal of biochemistry.

[10]  C. Schöneich,et al.  Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. , 2001, Journal of pharmaceutical sciences.

[11]  M. Churchill,et al.  Oxidation of a critical methionine modulates DNA binding of the Drosophila melanogaster high mobility group protein, HMG‐D , 1997, FEBS letters.

[12]  Langone Jj.  Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. , 1982 .

[13]  E. Stadtman,et al.  Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism , 2002, Molecular and Cellular Biochemistry.

[14]  M. Taussig,et al.  Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody—antigen interaction , 1997, Nature Structural Biology.

[15]  Leonard G Presta,et al.  Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. , 2006, International immunology.

[16]  A. West,et al.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. , 2001, Molecular cell.

[17]  Herren Wu,et al.  Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.

[18]  J L Cleland,et al.  Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. , 1997, Journal of pharmaceutical sciences.

[19]  Terrence G Oas,et al.  Methionine oxidation of monomeric lambda repressor: the denatured state ensemble under nondenaturing conditions. , 2006, Protein science : a publication of the Protein Society.

[20]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[21]  J. J. Langone.  Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. , 1982, Advances in immunology.

[22]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[23]  N. Tsurushita,et al.  An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.

[24]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[25]  J. Lin,et al.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. , 1992, The Journal of clinical investigation.

[26]  E Persson,et al.  Oxidation of methionine residues in coagulation factor VIIa. , 1999, Archives of biochemistry and biophysics.

[27]  P. Bjorkman,et al.  Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. , 1999, Biochemistry.

[28]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .

[29]  A. West,et al.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). , 2000, Biochemistry.

[30]  J. Tso,et al.  Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates* , 2004, Journal of Biological Chemistry.

[31]  N. Brot,et al.  Biochemistry and physiological role of methionine sulfoxide residues in proteins. , 1983, Archives of biochemistry and biophysics.

[32]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[33]  K. Mostov,et al.  An Fc receptor structurally related to MHC class I antigens , 1989, Nature.

[34]  Hongcheng Liu,et al.  Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[35]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[36]  Hongcheng Liu,et al.  Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  K Sasaoki,et al.  Oxidation of methionine residues of recombinant human interleukin 2 in aqueous solutions. , 1989, Chemical & pharmaceutical bulletin.

[38]  S. Langermann,et al.  Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.

[39]  A. Frelinger,et al.  The role of the methionine residues in the structure and function of parathyroid hormone. , 1986, Archives of biochemistry and biophysics.

[40]  K. Maggon,et al.  Monoclonal antibody "gold rush". , 2007, Current medicinal chemistry.

[41]  H. Friesen,et al.  Methionine oxidation in human growth hormone and human chorionic somatomammotropin. Effects on receptor binding and biological activities. , 1987, The Journal of biological chemistry.

[42]  D. Schoenfeld,et al.  Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn , 1996, Immunology.

[43]  R. Ober,et al.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.

[44]  Brian Hubbard,et al.  Downstream processing of monoclonal antibodies--application of platform approaches. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[45]  J. Sjödahl,et al.  Structural studies on the four repetitive Fc-binding regions in protein A from Staphylococcus aureus. , 1977, European journal of biochemistry.

[46]  G J Kleywegt,et al.  Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. , 1995, Structure.

[47]  H. Gouda,et al.  13C NMR study of the mode of interaction in solution of the B fragment of staphylococcal protein A and the Fc fragments of mouse immunoglobulin G , 1993, FEBS letters.

[48]  Linda O. Narhi,et al.  In Vitro Methionine Oxidation of Recombinant Human Leptin , 1998, Pharmaceutical Research.

[49]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[50]  D. Burton.  Immunoglobulin G: functional sites. , 1985, Molecular immunology.

[51]  Reed J. Harris,et al.  The application of tert-butylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody , 1996 .

[52]  B. Nidetzky,et al.  Single-Site Oxidation, Cysteine 108 to Cysteine Sulfinic Acid, in d-Amino Acid Oxidase from Trigonopsis variabilis and Its Structural and Functional Consequences , 2005, Applied and Environmental Microbiology.

[53]  C. Schöneich,et al.  Loss of conformational stability in calmodulin upon methionine oxidation. , 1998, Biophysical journal.

[54]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[55]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. , 2002, FEBS letters.